135 related articles for article (PubMed ID: 33333040)
1. Development and validation of a noninvasive clinical scoring system to predict significant fibrosis in patients with nonalcoholic fatty liver disease.
Jin W; Xu Y; Zhu W; Xia Z; Wu J
Clin Chim Acta; 2021 Mar; 514():48-53. PubMed ID: 33333040
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
3. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
4. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis.
Tavaglione F; Jamialahmadi O; De Vincentis A; Qadri S; Mowlaei ME; Mancina RM; Ciociola E; Carotti S; Perrone G; Bruni V; Gallo IF; Tuccinardi D; Bianco C; Prati D; Manfrini S; Pozzilli P; Picardi A; Caricato M; Yki-Järvinen H; Valenti L; Vespasiani-Gentilucci U; Romeo S
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1523-1532.e1. PubMed ID: 35421583
[TBL] [Abstract][Full Text] [Related]
6. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
[TBL] [Abstract][Full Text] [Related]
7. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
8. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease.
Ruffillo G; Fassio E; Alvarez E; Landeira G; Longo C; Domínguez N; Gualano G
J Hepatol; 2011 Jan; 54(1):160-3. PubMed ID: 20934232
[TBL] [Abstract][Full Text] [Related]
9. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.
Zhou YJ; Ye FZ; Li YY; Pan XY; Chen YX; Wu XX; Xiong JJ; Liu WY; Xu SH; Chen YP; Zheng MH
United European Gastroenterol J; 2019 Oct; 7(8):1124-1134. PubMed ID: 31662869
[TBL] [Abstract][Full Text] [Related]
10. Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD.
Feng G; Zheng KI; Li YY; Rios RS; Zhu PW; Pan XY; Li G; Ma HL; Tang LJ; Byrne CD; Targher G; He N; Mi M; Chen YP; Zheng MH
J Hepatobiliary Pancreat Sci; 2021 Jul; 28(7):593-603. PubMed ID: 33908180
[TBL] [Abstract][Full Text] [Related]
11. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
12. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
[TBL] [Abstract][Full Text] [Related]
15. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
16. A clinical and laboratory-based nomogram for predicting nonalcoholic fatty liver disease in non-diabetic adults: a cross-sectional study.
Qian Y; Sun B; Zhang Y; Zhang M; Jiao X; Lai L; Yang W
Ann Palliat Med; 2022 Jul; 11(7):2349-2359. PubMed ID: 35542976
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease.
Cen C; Wang W; Yu S; Tang X; Liu J; Liu Y; Zhou L; Yu J; Zheng S
Hepatol Int; 2020 Sep; 14(5):808-816. PubMed ID: 32572817
[TBL] [Abstract][Full Text] [Related]
18. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease.
de Carli MA; de Carli LA; Correa MB; Junqueira G; Tovo CV; Coral GP
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):420-425. PubMed ID: 31464779
[TBL] [Abstract][Full Text] [Related]
19. Validation of P2/MS and other noninvasive fibrosis scoring systems in the Korean population with nonalcoholic fatty liver disease.
Yu SJ; Kim DH; Lee JH; Chung GE; Yim JY; Park MJ; Kim YJ; Yoon JH; Jang JJ; Lee HS
Korean J Gastroenterol; 2011 Jan; 57(1):19-27. PubMed ID: 21258197
[TBL] [Abstract][Full Text] [Related]
20. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Angulo P; Hui JM; Marchesini G; Bugianesi E; George J; Farrell GC; Enders F; Saksena S; Burt AD; Bida JP; Lindor K; Sanderson SO; Lenzi M; Adams LA; Kench J; Therneau TM; Day CP
Hepatology; 2007 Apr; 45(4):846-54. PubMed ID: 17393509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
